An established drug for recurrent multiple myeloma might effectively be repurposed to improve the survival and day-to-day lives of patients with devastating sickle cell disease, according to revealing new research by a Feinstein Institute for Medical Research scientist.
The study, by Lionel Blanc, PhD, an assistant investigator at the Feinstein Institute, will be published Dec. 17 in the journal Blood. Dr. Blanc’s research, performed in collaboration with the New York Blood Center, Yale School of Medicine and University of Montpellier in France, was the first to identify how the drug pomalidomide increases production of fetal hemoglobin, known to interfere with the so-called “sickling” of red blood cells implicated in sickle cell disease (SCD).
Illuminating pomalidomide’s mechanism of action offers proof of concept that the US Food and Drug Administration (FDA)-approved medication could potentially be used to treat SCD, representing better outcomes compared to current drug treatment for the 100,000 Americans with SCD, an inherited disorder causing poor oxygen delivery, organ damage and even death.
“We knew the drug would make fetal hemoglobin, but we didn’t know to what extent or how. That was the goal of the study,” explained Dr. Blanc, also an assistant professor of molecular medicine and pediatrics at Hofstra North Shore-LIJ School of Medicine and an Allied World St. Baldrick’s Scholar.
“We can also say something else – that hydroxyurea, the only FDA-approved drug for sickle cell anemia, was less effective than pomalidomide and appeared to act through a different mechanism of action,” he added. “The current therapy is good, but not everyone responds equally to hydroxyurea, and what we hope with pomalidomide is to improve this.”
Pomalidomide, a derivative of thalidomide used in advanced cases of the cancer multiple myeloma, works by killing malignant plasma cells. But Dr. Blanc and his colleagues demonstrated in the new research, performed on stem cells taken from five SCD patients and 120 normal controls, how pomalidomide also generated fetal hemoglobin, the fetal version of the protein in red blood cells that carries oxygen to body tissues.
In patients with congenital conditions producing anemia such as SCD and beta-thalassemia, fetal hemoglobin is normal, but adult hemoglobin – produced after birth – is abnormal. Therefore, reversing their production of adult hemoglobin back to fetal hemoglobin can reverse the course of their disease.
In addition to the 100,000 US residents with SCD, the condition also affects millions globally. “I would remind people that anemia impacts 1.6 billion people worldwide, making it a global economic burden,” Dr. Blanc notes.
Dr. Blanc and his colleagues in the Division of Hematology/Oncology at Cohen Children’s Medical Center of New York plan to launch a clinical trial in the near future in collaboration with other institutions to test pomalidomide, which is taken orally, in young adults with SCD.
Currently, the only potential cures for SCD are gene therapy, still in the experimental stage, or stem cell transplant, but these resource-intense treatments aren’t available to the vast majority of patients, particularly in the developing world.
“Our hope is to alleviate the symptoms of sickle cell disease by using a pill that could be made available to almost all patients, worldwide,” Dr. Blanc said.
The Latest on: Sickle Cell Disease
via Google News
The Latest on: Sickle Cell Disease
- Agios's mitapivat an Orphan Drug in U.S. for sickle cell diseaseon November 12, 2020 at 7:06 pm
The FDA has designated Orphan drug status to (NASDAQ:AGIO) mitapivat, a pyruvate kinase R activator, for sickle cell disease.The company expects to initiate Phase 3 study of mitapivat in sickle cell ...
- Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Diseaseon November 12, 2020 at 1:44 pm
(GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug ...
- Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell ...on November 11, 2020 at 4:32 am
(GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease (SCD) treatments ...
- Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatmentson November 10, 2020 at 11:30 pm
Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease (SCD) treatments using its ...
- What Curing My Sickle Cell Disease Would Mean to Meon November 10, 2020 at 10:50 am
Or even worse, being labeled a typical sickle cell patient. It would mean finally being able to ... shared between a parent and child that comes with a genetically inherited disease. My mother could ...
- Forma Therapeutics' sickle cell candidate an orphan drug in Europeon November 10, 2020 at 9:29 am
FT-4202 for the treatment of sickle cell disease (SCD). The product candidate was previously granted Fast Track, Rare Pediatric Disease and Orphan Drug designations in the U.S. for SCD. The ...
- Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Diseaseon November 10, 2020 at 4:14 am
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the European Commission granted Orphan ...
- Bluebird bio's stock plunges after submission delay of sickle cell disease treatmenton November 5, 2020 at 7:11 am
Shares of Bluebird bio Inc. (BLUE) traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission for approval of its sickle cell disease ...
- Sickle Cell Anemia Testing and Screening - Global Market Outlook Report 2019-2027 - ResearchAndMarkets.comon November 3, 2020 at 6:25 am
Global Market Outlook (2019-2027)” report has been added to ResearchAndMarkets.com’s offering. Global Sickle Cell Anemia Testing and Screening Market accounted for $223.04 million in 2019 and is ...
- Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Diseaseon November 2, 2020 at 4:00 am
Global biotherapeutics leader CSL Behring announced today that its investigational, plasma-derived hemopexin therapy (CSL889) received ...
via Bing News